A Single-center, Randomized, Placebo-controlled, Parallel-group, Double-blind Study to Investigate the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of BAY 1817080 in Chinese Healthy Adult Male Participants.
Latest Information Update: 29 Nov 2021
At a glance
- Drugs Eliapixant (Primary)
- Indications Cough; Endometriosis; Neuropathic pain; Overactive bladder
- Focus Pharmacokinetics
- Sponsors Bayer
- 23 Nov 2021 Status changed from active, no longer recruiting to completed.
- 25 Sep 2021 Planned End Date changed from 1 Nov 2021 to 29 Oct 2021.
- 20 Jul 2021 Planned End Date changed from 21 Dec 2021 to 1 Nov 2021.